We would like to introduce a paper published by our client using our non-alcoholic steatohepatitis (NASH) model. (Murakami et al., Cells., 2022).

In this paper, the authors evaluated the effect of pemafibrate, a selective PPARα modulator, and tofogliflozin, an inhibitor of Na+/glucose-conjugated transport carrier 2, alone and in combination on the progression of NASH in the STAM™ mouse model. The use of pemafibrate and tofogliflozin, compounds with different mechanisms, was shown to have a synergistic effect.

The STAM™ model is the world's first mouse model to show the progression of NASH to liver cancer, and was developed here, at SMC Laboratories.

This model shows a pathology similar to human NASH (fatty liver → NASH → liver fibrosis → HCC).

Therefore, the STAM™ model has been used in many efficacy studies, as well as in basic research, and has also been used to test the effects of combination therapy with various compounds.

Would you like to use the STAM™ model to test the efficacy of your compound in monotherapy or combination therapy? We can use our years of experience to offer you a study design that is tailored to suit your needs.

If you are interested in using our STAM™ model, please do not hesitate to reach out!